Below are the most recent publications written about "Maintenance Chemotherapy" by people in Profiles.
-
Moses J, Adler J, Saeed SA, Firestine AM, Galanko JA, Ammoury RF, Bass DM, Bass JA, Bastidas M, Benkov KJ, Bousvaros A, Cabrera JM, Chun KY, Dorsey JM, Ebach DR, Gulati AS, Herfarth HH, Ivanova A, Jester TW, Kaplan JL, Kusek ME, Leibowitz IH, Linville TM, Margolis PA, Minar P, Molle-Rios Z, Niklinska-Schirtz BJ, Olano KK, Osaba L, Palomo PJ, Pashankar DS, Pitch L, Samson CM, Sandberg KC, Steiner SJ, Strople JA, Sullivan JS, Tung J, Wali P, Wohl DA, Zikry M, Boyle BM, Kappelman MD. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease. Inflamm Bowel Dis. 2025 Jul 07; 31(7):1841-1850.
-
Gyan E, Minden MD, Kubo K, Rambaldi A, Juliusson G, J?dersten M, Kelly RJ, Szerafin L, He W, Gill SC, Hill JE, Chen C, Delgado D, Hasabou N. Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. Cancer. 2025 Feb 15; 131(4):e35746.
-
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, P?rez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, Gonz?lez-Mart?n A. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992.
-
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022 Feb 01; 327(5):464-477.
-
Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021 02 04; 11(2):23.
-
Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Pan?s J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020 01; 51(2):271-280.
-
Gonz?lez-Mart?n A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-P?rez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2391-2402.
-
Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. J Low Genit Tract Dis. 2018 Oct; 22(4):382-386.
-
Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the?efficacy and safety of orally administered?VT-1161 in?the treatment of recurrent?vulvovaginal candidiasis. Am J Obstet Gynecol. 2018 06; 218(6):624.e1-624.e9.